research ROS Balance Autoregulating Core–Shell CeO2@ZIF-8/Au Nanoplatform for Wound Repair
The nanoplatform helps heal wounds by balancing bacteria-killing and inflammation-reducing functions.
Search
for
Sort by
Research
180-210 / 1000+ results research A Case of Rhupus with Rowell Syndrome
A woman with Rhupus and Rowell syndrome was treated successfully with medication adjustments.
research Thiazole: A Versatile Standalone Moiety Contributing to the Development of Various Drugs and Biologically Active Agents
Thiazole, a sulfur and nitrogen chemical, is useful in creating potential drugs for conditions like seizures, cancer, bacterial infections, tuberculosis, inflammation, malaria, viruses, Alzheimer's, diabetes, and A1-receptor issues.
research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Polyphenolization:Hair Browning by Phenolic Adhesion,Ambient Oxygen, and Transition Metals
A new hair dye method uses polyphenols and oxidation to create a long-lasting brown color on gray hair.
research Radon. Radium, and Uranium Levels in Some Samples of women Hair Treatment Materials
The hair treatment materials are safe to use.
research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
research Hyperpigmentation, severe alopecia, and six days of instability in a case of severe methotrexate hypersensitivity reaction
A woman had severe reactions to methotrexate, including skin issues and organ problems, but improved after 38 days in the hospital.
research Long-term toxicity studies on oxidation hair dyes
The hair dye formulations tested did not cause long-term toxicity or cancer in mice.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators
PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
RC48 shows promise for treating certain advanced cancers, but more research is needed.
research Ponatinib-induced pityriasis rubra pilaris-like adnexal dysmaturation: A case report
Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
research A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty
Triptorelin effectively treats central precocious puberty in Chinese children with minimal side effects.
research How useful is ritlecitinib in alopecia areata?
Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
research Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
research How useful is ritlecitinib in alopecia areata?
Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians
Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
research Recombinant Thrombomodulin Used to Successfully Treat Cronkhite-Canada Syndrome with Disseminated Intravascular Coagulation due to Sepsis in a Compromised Patient
Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.
research Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
Ritlecitinib effectively treats alopecia areata with manageable side effects.
research A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
research Clobetasol/minoxidil
research Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
research 1P-230: Synthesis and in vitro characterization of 68 Ga labeled Fe 3 O 4 nanoparticles for drug delivery
The nanoparticles show promise for cancer treatment and diagnosis with fewer side effects.
research Long-term toxicologic and tumorigenesis studies on an oral contraceptive agent in albino rats
research AB0389 Methotrexate Treatment for Rheumatoid Arthritis in Poland: Retrospective Analysis of Patients in Routine Clinical Practice
Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.